Myriad Genetics Inc. has announced the early access launch of its FirstGene Multiple Prenatal Screen through a large-scale clinical study. The screen aims to provide a comprehensive prenatal risk assessment for common genetic conditions with a single blood draw, eliminating the need for paternal testing. This initiative, part of the CONNECTOR study, will enroll over 5,000 patients across various clinical sites to evaluate the screen's effectiveness in real-world settings. The FirstGene screen has demonstrated more than 98.6% sensitivity and 99.6% specificity in previous tests. The study will generate clinical validity and utility evidence for the FirstGene screen as Myriad Genetics seeks to expand its prenatal portfolio.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Myriad Genetics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9461913-en) on June 03, 2025, and is solely responsible for the information contained therein.